Effects of Mebudipine and Dibudipine, Two New Calcium-channel Blockers, on Rat Left Atrium, Rat Blood Pressure and Human Internal Mammary Artery

Mebudipine and dibudipine are two new dihydropyridine calcium‐channel blockers that have been synthesized in our laboratory. In a previous study, they showed considerable relaxant effect on vascular and ileal smooth muscle. Here, the pharmacological effects of mebudipine and dibudipine on isolated r...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of pharmacy and pharmacology 1999-05, Vol.51 (5), p.617-622
Hauptverfasser: MIRKHANI, H., OMRANI, G. R., GHIAEE, S., MAHMOUDIAN, M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 622
container_issue 5
container_start_page 617
container_title Journal of pharmacy and pharmacology
container_volume 51
creator MIRKHANI, H.
OMRANI, G. R.
GHIAEE, S.
MAHMOUDIAN, M.
description Mebudipine and dibudipine are two new dihydropyridine calcium‐channel blockers that have been synthesized in our laboratory. In a previous study, they showed considerable relaxant effect on vascular and ileal smooth muscle. Here, the pharmacological effects of mebudipine and dibudipine on isolated rat left atrium, rat blood pressure and isolated human internal mammary artery are described. Results are compared with those obtained for nifedipine. Mebudipine and dibudipine reduced contraction force of rat left atrium (pIC30 values: 5·37 ± 0·13 and 5·49 ± 0·15, respectively) but their negative inotropic effects were significantly weaker than that of nifedipine (pIC30 value: 6·63 ± 0·11). Mebudipine and dibudipine lowered rat blood pressure. The hypotensive effect of mebudipine was similar to that of nifedipine while dibudipine was weaker than nifedipine. It was found that the half‐life of the hypotensive action of dibudipine (41·91 ± 3·77 min, 31·13 ± 2·26 min and 28·20 ± 4·37 min at 2, 4 and 8 mg kg−1 orally administered doses, respectively) was longer than that of nifedipine (11·85 ± 2·88 min, 16·65 ± 2·42 min and 14·03 ± 0·10 min at the same doses, respectively). Also, it appeared that mebudipine had a slower rate of absorption compared with nifedipine (the time to reach peak hypotensive action at 2, 4 and 8 mg kg−1 orally administered doses were, respectively, 24·00 ± 6·96 min, 23·75 ± 2·39 min and 15·00 ± 2·04 min for mebudipine and 7·80 ± 0·86 min, 13·75 ± 3·15 min and 8·33 ± 0·88 min for nifedipine). The two new compounds, as well as nifedipine, relaxed KCl‐treated isolated human internal mammary artery (pEC50 values; 7·87 ± 0·12, 7·22 ± 0·24 and 7·67 ± 0·12 for mebudipine, dibudipine and nifedipine, respectively). The relaxant effects of mebudipine and dibudipine did not show any significant difference compared with that of nifedipine. It is concluded that these new compounds are weak cardiodepressants and, with due attention to its significant vasorelaxant action, mebudipine is a vasoselective compound. In addition, these two compounds have potent blood pressure lowering effects. Also, their vasorelaxant action can be reproduced in human vascular preparations.
doi_str_mv 10.1211/0022357991772727
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69895671</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69895671</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4526-209fcf0a65e25bbdef5d7cc51d9a7bbff8f46dfaede84d4d4625114c60c7cf5a3</originalsourceid><addsrcrecordid>eNqFkUGP0zAQhS0EYsvCnRPyiVMDthPbybGUZbuoLRW7CG6WY49F2MQpdqLSf8FPxiULQlxWcxjNzPeeNHoIPafkFWWUviaEsZzLqqJSslQP0IyRgmWS8vIhmp3OWbrnZ-hJjN8IIVII8RidUVJQyhiboZ8XzoEZIu4d3kA92mbfeMDaW_y2-TPO8c2hx1s44KVuTTN2mfmqvYcWv2l7cwshznHv8Uc94DW4AS-GkKD570Uieot3AWIcw2S8Gjvt8ZUfIHjd4o3uOh2OeBHS4vgUPXK6jfDsrp-jT-8ubparbP3h8mq5WGem4ExkjFTOOKIFB8br2oLjVhrDqa20rGvnSlcI6zRYKAubSjBOaWEEMdI4rvNz9HLy3Yf--whxUF0TDbSt9tCPUYmqrLiQ9F6QEUFFWRQJJBNoQh9jAKf2oTl9pihRp7jU_3ElyYs777HuwP4jmPJJAJ-AQ9PC8V5D9X632nEuki6bdE0c4MdfnQ63SshccvV5e6mut5svOyq4us5_ATY5rzo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20616844</pqid></control><display><type>article</type><title>Effects of Mebudipine and Dibudipine, Two New Calcium-channel Blockers, on Rat Left Atrium, Rat Blood Pressure and Human Internal Mammary Artery</title><source>Wiley-Blackwell Journals</source><source>MEDLINE</source><source>Oxford University Press</source><creator>MIRKHANI, H. ; OMRANI, G. R. ; GHIAEE, S. ; MAHMOUDIAN, M.</creator><creatorcontrib>MIRKHANI, H. ; OMRANI, G. R. ; GHIAEE, S. ; MAHMOUDIAN, M.</creatorcontrib><description>Mebudipine and dibudipine are two new dihydropyridine calcium‐channel blockers that have been synthesized in our laboratory. In a previous study, they showed considerable relaxant effect on vascular and ileal smooth muscle. Here, the pharmacological effects of mebudipine and dibudipine on isolated rat left atrium, rat blood pressure and isolated human internal mammary artery are described. Results are compared with those obtained for nifedipine. Mebudipine and dibudipine reduced contraction force of rat left atrium (pIC30 values: 5·37 ± 0·13 and 5·49 ± 0·15, respectively) but their negative inotropic effects were significantly weaker than that of nifedipine (pIC30 value: 6·63 ± 0·11). Mebudipine and dibudipine lowered rat blood pressure. The hypotensive effect of mebudipine was similar to that of nifedipine while dibudipine was weaker than nifedipine. It was found that the half‐life of the hypotensive action of dibudipine (41·91 ± 3·77 min, 31·13 ± 2·26 min and 28·20 ± 4·37 min at 2, 4 and 8 mg kg−1 orally administered doses, respectively) was longer than that of nifedipine (11·85 ± 2·88 min, 16·65 ± 2·42 min and 14·03 ± 0·10 min at the same doses, respectively). Also, it appeared that mebudipine had a slower rate of absorption compared with nifedipine (the time to reach peak hypotensive action at 2, 4 and 8 mg kg−1 orally administered doses were, respectively, 24·00 ± 6·96 min, 23·75 ± 2·39 min and 15·00 ± 2·04 min for mebudipine and 7·80 ± 0·86 min, 13·75 ± 3·15 min and 8·33 ± 0·88 min for nifedipine). The two new compounds, as well as nifedipine, relaxed KCl‐treated isolated human internal mammary artery (pEC50 values; 7·87 ± 0·12, 7·22 ± 0·24 and 7·67 ± 0·12 for mebudipine, dibudipine and nifedipine, respectively). The relaxant effects of mebudipine and dibudipine did not show any significant difference compared with that of nifedipine. It is concluded that these new compounds are weak cardiodepressants and, with due attention to its significant vasorelaxant action, mebudipine is a vasoselective compound. In addition, these two compounds have potent blood pressure lowering effects. Also, their vasorelaxant action can be reproduced in human vascular preparations.</description><identifier>ISSN: 0022-3573</identifier><identifier>EISSN: 2042-7158</identifier><identifier>DOI: 10.1211/0022357991772727</identifier><identifier>PMID: 10411222</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Animals ; Blood Pressure - drug effects ; Calcium Channel Blockers - pharmacology ; Heart Atria - drug effects ; Humans ; Male ; Mammary Arteries - drug effects ; Nifedipine - analogs &amp; derivatives ; Nifedipine - pharmacology ; Rats ; Rats, Sprague-Dawley</subject><ispartof>Journal of pharmacy and pharmacology, 1999-05, Vol.51 (5), p.617-622</ispartof><rights>1999 Royal Pharmaceutical Society of Great Britain</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4526-209fcf0a65e25bbdef5d7cc51d9a7bbff8f46dfaede84d4d4625114c60c7cf5a3</citedby><cites>FETCH-LOGICAL-c4526-209fcf0a65e25bbdef5d7cc51d9a7bbff8f46dfaede84d4d4625114c60c7cf5a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1211%2F0022357991772727$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1211%2F0022357991772727$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27915,27916,45565,45566</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10411222$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MIRKHANI, H.</creatorcontrib><creatorcontrib>OMRANI, G. R.</creatorcontrib><creatorcontrib>GHIAEE, S.</creatorcontrib><creatorcontrib>MAHMOUDIAN, M.</creatorcontrib><title>Effects of Mebudipine and Dibudipine, Two New Calcium-channel Blockers, on Rat Left Atrium, Rat Blood Pressure and Human Internal Mammary Artery</title><title>Journal of pharmacy and pharmacology</title><addtitle>J Pharm Pharmacol</addtitle><description>Mebudipine and dibudipine are two new dihydropyridine calcium‐channel blockers that have been synthesized in our laboratory. In a previous study, they showed considerable relaxant effect on vascular and ileal smooth muscle. Here, the pharmacological effects of mebudipine and dibudipine on isolated rat left atrium, rat blood pressure and isolated human internal mammary artery are described. Results are compared with those obtained for nifedipine. Mebudipine and dibudipine reduced contraction force of rat left atrium (pIC30 values: 5·37 ± 0·13 and 5·49 ± 0·15, respectively) but their negative inotropic effects were significantly weaker than that of nifedipine (pIC30 value: 6·63 ± 0·11). Mebudipine and dibudipine lowered rat blood pressure. The hypotensive effect of mebudipine was similar to that of nifedipine while dibudipine was weaker than nifedipine. It was found that the half‐life of the hypotensive action of dibudipine (41·91 ± 3·77 min, 31·13 ± 2·26 min and 28·20 ± 4·37 min at 2, 4 and 8 mg kg−1 orally administered doses, respectively) was longer than that of nifedipine (11·85 ± 2·88 min, 16·65 ± 2·42 min and 14·03 ± 0·10 min at the same doses, respectively). Also, it appeared that mebudipine had a slower rate of absorption compared with nifedipine (the time to reach peak hypotensive action at 2, 4 and 8 mg kg−1 orally administered doses were, respectively, 24·00 ± 6·96 min, 23·75 ± 2·39 min and 15·00 ± 2·04 min for mebudipine and 7·80 ± 0·86 min, 13·75 ± 3·15 min and 8·33 ± 0·88 min for nifedipine). The two new compounds, as well as nifedipine, relaxed KCl‐treated isolated human internal mammary artery (pEC50 values; 7·87 ± 0·12, 7·22 ± 0·24 and 7·67 ± 0·12 for mebudipine, dibudipine and nifedipine, respectively). The relaxant effects of mebudipine and dibudipine did not show any significant difference compared with that of nifedipine. It is concluded that these new compounds are weak cardiodepressants and, with due attention to its significant vasorelaxant action, mebudipine is a vasoselective compound. In addition, these two compounds have potent blood pressure lowering effects. Also, their vasorelaxant action can be reproduced in human vascular preparations.</description><subject>Animals</subject><subject>Blood Pressure - drug effects</subject><subject>Calcium Channel Blockers - pharmacology</subject><subject>Heart Atria - drug effects</subject><subject>Humans</subject><subject>Male</subject><subject>Mammary Arteries - drug effects</subject><subject>Nifedipine - analogs &amp; derivatives</subject><subject>Nifedipine - pharmacology</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><issn>0022-3573</issn><issn>2042-7158</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUGP0zAQhS0EYsvCnRPyiVMDthPbybGUZbuoLRW7CG6WY49F2MQpdqLSf8FPxiULQlxWcxjNzPeeNHoIPafkFWWUviaEsZzLqqJSslQP0IyRgmWS8vIhmp3OWbrnZ-hJjN8IIVII8RidUVJQyhiboZ8XzoEZIu4d3kA92mbfeMDaW_y2-TPO8c2hx1s44KVuTTN2mfmqvYcWv2l7cwshznHv8Uc94DW4AS-GkKD570Uieot3AWIcw2S8Gjvt8ZUfIHjd4o3uOh2OeBHS4vgUPXK6jfDsrp-jT-8ubparbP3h8mq5WGem4ExkjFTOOKIFB8br2oLjVhrDqa20rGvnSlcI6zRYKAubSjBOaWEEMdI4rvNz9HLy3Yf--whxUF0TDbSt9tCPUYmqrLiQ9F6QEUFFWRQJJBNoQh9jAKf2oTl9pihRp7jU_3ElyYs777HuwP4jmPJJAJ-AQ9PC8V5D9X632nEuki6bdE0c4MdfnQ63SshccvV5e6mut5svOyq4us5_ATY5rzo</recordid><startdate>199905</startdate><enddate>199905</enddate><creator>MIRKHANI, H.</creator><creator>OMRANI, G. R.</creator><creator>GHIAEE, S.</creator><creator>MAHMOUDIAN, M.</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7X8</scope></search><sort><creationdate>199905</creationdate><title>Effects of Mebudipine and Dibudipine, Two New Calcium-channel Blockers, on Rat Left Atrium, Rat Blood Pressure and Human Internal Mammary Artery</title><author>MIRKHANI, H. ; OMRANI, G. R. ; GHIAEE, S. ; MAHMOUDIAN, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4526-209fcf0a65e25bbdef5d7cc51d9a7bbff8f46dfaede84d4d4625114c60c7cf5a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Animals</topic><topic>Blood Pressure - drug effects</topic><topic>Calcium Channel Blockers - pharmacology</topic><topic>Heart Atria - drug effects</topic><topic>Humans</topic><topic>Male</topic><topic>Mammary Arteries - drug effects</topic><topic>Nifedipine - analogs &amp; derivatives</topic><topic>Nifedipine - pharmacology</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MIRKHANI, H.</creatorcontrib><creatorcontrib>OMRANI, G. R.</creatorcontrib><creatorcontrib>GHIAEE, S.</creatorcontrib><creatorcontrib>MAHMOUDIAN, M.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pharmacy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MIRKHANI, H.</au><au>OMRANI, G. R.</au><au>GHIAEE, S.</au><au>MAHMOUDIAN, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of Mebudipine and Dibudipine, Two New Calcium-channel Blockers, on Rat Left Atrium, Rat Blood Pressure and Human Internal Mammary Artery</atitle><jtitle>Journal of pharmacy and pharmacology</jtitle><addtitle>J Pharm Pharmacol</addtitle><date>1999-05</date><risdate>1999</risdate><volume>51</volume><issue>5</issue><spage>617</spage><epage>622</epage><pages>617-622</pages><issn>0022-3573</issn><eissn>2042-7158</eissn><abstract>Mebudipine and dibudipine are two new dihydropyridine calcium‐channel blockers that have been synthesized in our laboratory. In a previous study, they showed considerable relaxant effect on vascular and ileal smooth muscle. Here, the pharmacological effects of mebudipine and dibudipine on isolated rat left atrium, rat blood pressure and isolated human internal mammary artery are described. Results are compared with those obtained for nifedipine. Mebudipine and dibudipine reduced contraction force of rat left atrium (pIC30 values: 5·37 ± 0·13 and 5·49 ± 0·15, respectively) but their negative inotropic effects were significantly weaker than that of nifedipine (pIC30 value: 6·63 ± 0·11). Mebudipine and dibudipine lowered rat blood pressure. The hypotensive effect of mebudipine was similar to that of nifedipine while dibudipine was weaker than nifedipine. It was found that the half‐life of the hypotensive action of dibudipine (41·91 ± 3·77 min, 31·13 ± 2·26 min and 28·20 ± 4·37 min at 2, 4 and 8 mg kg−1 orally administered doses, respectively) was longer than that of nifedipine (11·85 ± 2·88 min, 16·65 ± 2·42 min and 14·03 ± 0·10 min at the same doses, respectively). Also, it appeared that mebudipine had a slower rate of absorption compared with nifedipine (the time to reach peak hypotensive action at 2, 4 and 8 mg kg−1 orally administered doses were, respectively, 24·00 ± 6·96 min, 23·75 ± 2·39 min and 15·00 ± 2·04 min for mebudipine and 7·80 ± 0·86 min, 13·75 ± 3·15 min and 8·33 ± 0·88 min for nifedipine). The two new compounds, as well as nifedipine, relaxed KCl‐treated isolated human internal mammary artery (pEC50 values; 7·87 ± 0·12, 7·22 ± 0·24 and 7·67 ± 0·12 for mebudipine, dibudipine and nifedipine, respectively). The relaxant effects of mebudipine and dibudipine did not show any significant difference compared with that of nifedipine. It is concluded that these new compounds are weak cardiodepressants and, with due attention to its significant vasorelaxant action, mebudipine is a vasoselective compound. In addition, these two compounds have potent blood pressure lowering effects. Also, their vasorelaxant action can be reproduced in human vascular preparations.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>10411222</pmid><doi>10.1211/0022357991772727</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-3573
ispartof Journal of pharmacy and pharmacology, 1999-05, Vol.51 (5), p.617-622
issn 0022-3573
2042-7158
language eng
recordid cdi_proquest_miscellaneous_69895671
source Wiley-Blackwell Journals; MEDLINE; Oxford University Press
subjects Animals
Blood Pressure - drug effects
Calcium Channel Blockers - pharmacology
Heart Atria - drug effects
Humans
Male
Mammary Arteries - drug effects
Nifedipine - analogs & derivatives
Nifedipine - pharmacology
Rats
Rats, Sprague-Dawley
title Effects of Mebudipine and Dibudipine, Two New Calcium-channel Blockers, on Rat Left Atrium, Rat Blood Pressure and Human Internal Mammary Artery
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T20%3A21%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20Mebudipine%20and%20Dibudipine,%20Two%20New%20Calcium-channel%20Blockers,%20on%20Rat%20Left%20Atrium,%20Rat%20Blood%20Pressure%20and%20Human%20Internal%20Mammary%20Artery&rft.jtitle=Journal%20of%20pharmacy%20and%20pharmacology&rft.au=MIRKHANI,%20H.&rft.date=1999-05&rft.volume=51&rft.issue=5&rft.spage=617&rft.epage=622&rft.pages=617-622&rft.issn=0022-3573&rft.eissn=2042-7158&rft_id=info:doi/10.1211/0022357991772727&rft_dat=%3Cproquest_cross%3E69895671%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20616844&rft_id=info:pmid/10411222&rfr_iscdi=true